Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Other Operating Expenses: 2017-2025

Historic Other Operating Expenses for Puma Biotechnology (PBYI) over the last 8 years, with Sep 2025 value amounting to $12.2 million.

  • Puma Biotechnology's Other Operating Expenses fell 58.16% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.0 million, marking a year-over-year decrease of 34.56%. This contributed to the annual value of $64.4 million for FY2024, which is 2.75% up from last year.
  • Puma Biotechnology's Other Operating Expenses amounted to $12.2 million in Q3 2025, which was down 1.04% from $12.3 million recorded in Q2 2025.
  • Over the past 5 years, Puma Biotechnology's Other Operating Expenses peaked at $29.6 million during Q1 2021, and registered a low of $10.3 million during Q3 2021.
  • Moreover, its 3-year median value for Other Operating Expenses was $12.3 million (2025), whereas its average is $14.7 million.
  • Per our database at Business Quant, Puma Biotechnology's Other Operating Expenses spiked by 225.66% in 2021 and then plummeted by 63.31% in 2022.
  • Puma Biotechnology's Other Operating Expenses (Quarterly) stood at $11.9 million in 2021, then surged by 41.54% to $16.8 million in 2022, then surged by 44.47% to $24.3 million in 2023, then plummeted by 42.77% to $13.9 million in 2024, then tumbled by 58.16% to $12.2 million in 2025.
  • Its Other Operating Expenses stands at $12.2 million for Q3 2025, versus $12.3 million for Q2 2025 and $10.6 million for Q1 2025.